A new gold nanoparticle based rapid immunochromatographic assay for screening EBV-VCA specific IgA in nasopharyngeal carcinomas

Journal of Applied Biomedicine

Volumn 13, Issue 2, 2015, Pages 123-129

  Goudarzi, Saeid ^a   Ahmadi, Anita ^b   Farhadi, Mohammad ^a   Kamrava, Seyed Kamran ^a   Mobarrez, Fariborz ^c   Omidfar, Kobra ^b  

^a Iran University of Medical Sciences   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer biomarker; EBV VCA IgA; Gold nanoparticle; Immunochromatography; Nasopharyngeal carcinoma; Screening test

Indexed keywords

COLLOIDAL GOLD; EPSTEIN BARR VIRUS ANTIGEN; GOLD NANOPARTICLE; IMMUNOGLOBULIN A ANTIBODY; VIRUS CAPSID ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SCREENING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONJUGATE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; LIMIT OF DETECTION; MALE; NASOPHARYNX CARCINOMA; OPTICAL DENSITY; PARTICLE SIZE; RAPID TEST; SENSITIVITY AND SPECIFICITY; TEST STRIP;

EID: 84984851227     PISSN: 1214021X     EISSN: 12140287     Source Type: Journal    
DOI: 10.1016/j.jab.2014.08.001     Document Type: Article

References (39)

1. Cao, S.M., Liu1, Z., Jia, W.H., et al. Fluctuations of Epstein–Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One, 22, 2011, e19100.
2. Chang, E.T., Adami, H.O., The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 15 (2006), 1765–1777.
3. Chen, J.Y., Chen, C.J., Liu, M.Y., et al. Antibody to Epstein–Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J. Med. Virol. 27 (1989), 269–273.
4. Chien, Y.C., Chen, J.Y., Liu, M.Y., et al. Serologic markers of Epstein–Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 345 (2001), 1877–1882.
5. Chi-shing Cho, W., Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol. Cancer, 6, 2007, 1.
6. Deng, H., Zhao, Z., Zhang, Z., Serologic screening on nasopharyngeal cancer in 338,868 persons in 21 cities and counties of Guangxi Region, China. Zhonghua Yu Fang Yi Xue Za Zhi 29 (1995), 342–343.
7. Fachiroh, J., Paramita, D.K., Hariwiyanto, B., et al. Single-assay combination of Epstein–Barr virus (EBV) EBNA-1 and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J. Clin. Microbiol. 44 (2006), 1459–1467.
8. Gui, W.J., Wang, S.T., Guo, Y.R., Zhu, G.N., Development of a one-step strip for the detection of triazophos residues in environmental samples. Anal. Biochem. 377 (2008), 202–208.
9. Henle, G., Henle, W., Epstein–Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer 17 (1976), 1–7.
10. Henle, W., Ho, H.C., Henle, G., Kwan, H.C., Antibodies to Epstein–Barr virus-related antigens in nasopharyngeal carcinoma. Comparison of active cases with long-term survivors. J. Natl. Cancer Inst. 51 (1973), 361–369.
11. Ho, D.W., Yang, Z.F., Wong, B.Y., et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. Cancer 107 (2006), 99–107.
12. Jemal, A., Bray, F., Center, M., Ferlay, J., Ward, E., Forman, D., Global cancer Statistics. CA Cancer J. Clin. 61 (2011), 69–90.
13. Jiang, L.N., Dai, L.C., He, J.F., Chen, Y.W., Ma, Z.H., Significance of detection of serum sialic acid and Epstein–Barr virus VCA-IgA in diagnosis and monitoring radiotherapy effectiveness in nasopharyngeal carcinoma patients. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 20 (2006), 30–32.
14. Kao, C.H., Shiau, Y.U.C., Shen, Y.Y., Yen, R.F., Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with technetium-99m methoxyisobutylisonitrile single photon emission computed tomography and computed tomography: comparison with 18-fluoro-2-deoxyglucose positron emission tomography. Chin. J. Cancer 94 (2002), 1981–1986.
15. King, A.D., Vlantis, A.C., Bhatia, K.S.S., et al. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. Radiology 258 (2011), 531–537.
16. Lee, E.Y., Kang, J.H., Kim, K.A., et al. Development of a rapid immunochromatographic strip test for serum asialo alpha1acid glycoprotein in patients with hepatic disease. J. Immunol. Methods 308 (2006), 116–123.
17. Lo, Y.M., Chan, L.Y., Lo, K.W., et al. Quantitative analysis of cell-free Epstein–Barr virus DNA in plasma of patients with nasopharyngeal cancer. Cancer Res. 59 (1999), 1188–1191.
18. Low, W.K., Leong, J.L., Goh, Y.H., Fong, K.W., Diagnostic value of Epstein–Barr viral serology in nasopharyngeal carcinoma. Otolaryngol. Head Neck Surg. 123 (2000), 505–507.
19. Lynn, T.C., Hsieh, R.P., Chuang, C.Y., Huang, S.C., Hsieh, T., Tu, S.M., Epstein–Barr virus-associated antibodies and serum biochemistry in nasopharyngeal carcinoma. Laryngoscope 94 (1984), 1485–1488.
20. Molinelli, A., Grossalber, K., Führer, M., Baumgartner, S., Sulyok, M., Krska, R., Development of qualitative and semiquantitative immunoassay-based rapid strip tests for the detection of T-2 toxin in wheat and oat. J. Agric. Food Chem. 56 (2008), 2589–2594.
21. Mousavi, S.M., National Cancer Registry Report 2005–2006., 2006, Ministry of Health, Deputy for Health Directory, CDC Cancer Office, Tehran, Iran (Persian).
22. Nagatani, N., Yuhi, T., Chikae, M., et al. A sensitive immunochromatographic assay using gold nanoparticles for the semiquantitative detection of prostate-specific antigen in serum. Nanobiotechnology 2 (2006), 79–86.
23. Neel, H.B. III, Pearson, G.R., Weiland, L.H., et al. Application of Epstein–Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. Otolaryngol. Head Neck Surg. 91 (1983), 255–262.
24. Neel, H.B. III, Pearson, G.R., Taylor, W.F., Antibodies to Epstein–Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. Ann. Otol. Rhinol. Laryngol. 93 (1984), 477–482.
25. Omidfar, K., Kia, S., Kashanian, S., et al. Colloidal nanogold-based immunochromatographic strip test for the detection of digoxin toxicity. Appl. Biochem. Biotechnol. 160 (2010), 843–855.
26. Omidfar, K., Kia, S., Larijani, B., Development of a colloidal gold-based immunochromatographic test strip for screening of microalbuminuria. Hybridoma 30 (2011), 117–124.
27. Omidfar, K., Khorsand, B., Larijani, B., Development of a new sensitive immunostrip assay based on mesoporous silica and colloidal Au nanoparticles. Mol. Biol. Rep. 39 (2012), 1253–1259.
28. Omidfar, K., Zarei, H., Gholizadeh, F., Larijani, B., A high-sensitivity electrochemical immunosensor based on mobile crystalline material-41-polyvinyl alcohol nanocomposite and colloidal gold nanoparticles. Anal. Biochem. 421 (2012), 649–656.
29. Omidfar, K., Khorsand, F., Darziani Azizi, M., New analytical applications of gold nanoparticles as label in antibody based sensors. Biosens. Bioelectron. 26 (2013), 336–347.
30. Parkin, D.M., Bray, F., Ferlay, J., Pisani, P., Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005), 74–108.
31. Raah-Trauh, N., Epstein–Barr virus aiid nasopharyngeal carcinoma. Semin. Cancer Biol. 3 (1992), 297–307.
32. Sacmundsen, A.K., Aiheck, H., Hansen, J.P.H., Epstein–Barr virus in nasopharyngeal attd salivary gland carcinomas in Greenland Eskimos. Br. J. Cancer 46 (1982), 721–728.
33. Saika, K., Sobue, T., Comparison of time trends in cancer incidence (1973–2002) in Asia, from cancer incidence in five continents Vols IV–IX. Jpn. J. Clin. Oncol. 38 (2008), 872–873.
34. Shanmugaratnam, K., Chan, S.H., de-The, G., et al. Histopathology of nasopharyngeal carcinoma. Correlations with epidemiology, survival rates and other biological characteristics. Cancer 44 (1979), 1029–1044.
35. Shimakage, M., Ikegami, N., Chatani, M., Yoshino, K., Sato, T., Serological follow-up study on the antibody levels to Epstein–Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy. Biken J. 30 (1987), 45–51.
36. Xiulan, S., Xiaolian, Z., Jian, T., Zhou, J., Chu, F., Preparation of gold-labeled antibody probe and its use in immunochromatography assay for detection of aflatoxin B1. Int. J. Food Microbiol. 99 (2005), 185–194.
37. Yen, R.F., Hong, R.L., Tzen, K.Y., Pan, M.H., Chen, T.H.H., Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J. Nucl. Med. 46 (2005), 770–774.
38. Yen, R.F., Hung, R.L., Pan, M.H., et al. 18-Fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging. Chin. J. Cancer 98 (2003), 283–287.
39. Zeng, Y., Zhang, L.G., Li, H.Y., et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int. J. Cancer 29 (1982), 139–141.